Topics

Eisai Buys Out Purdue’s Rights in Worldwide Collaboration for Development and Commercialization of Lemborexant

16:46 EDT 1 May 2019 | Speciality Pharma Journal

WOODCLIFF LAKE, N.J. and STAMFORD, Conn., April 30, 2019 /PRNewswire/ — Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue’s rights to the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular …

Original Article: Eisai Buys Out Purdue’s Rights in Worldwide Collaboration for Development and Commercialization of Lemborexant

NEXT ARTICLE

More From BioPortfolio on "Eisai Buys Out Purdue’s Rights in Worldwide Collaboration for Development and Commercialization of Lemborexant"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...